FDA Approved 1,014 Generic Drugs in 2019
Approvals were down slightly year over year.
Mylan
MYL
MYL
$21.15
$0.22
1.1%
Price as of February 21, 2020, 4:30 p.m. EST
View Interactive MYL Charts
The Company develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients.
Interactive Chart
News & Analysis: Mylan
The Fool has written over 200 articles on Mylan.
Is Mylan Stock a Buy?
Mylan’s planned combination with Upjohn is a bright spot for investors, but the difficulties of the U.S. generic-drug market remain a potential obstacle.
Here's Why Mylan Fell 26.6% in 2019
It was a trying year for the generic drug manufacturer. Can a combination with Pfizer help to soothe beleaguered investors?
California Governor Gavin Newsom Proposes State-Run Prescription Drug Label
The idea is among a set of proposals aimed at cooling healthcare costs in the state.
Mylan Issues Nationwide Recall for Contaminated Ulcer Medication
Trace amounts of carcinogens were found in Mylan's nizatidine capsules.
Mylan N.V. (MYL) Q3 2019 Earnings Call Transcript
MYL earnings call for the period ending September 30, 2019.
Will a $48 Billion Global Settlement End U.S. Opioid Crisis Lawsuits?
A settlement in a closely watched Ohio case averted a federal trial and paves the way to a nationwide settlement -- if drug companies shorten their payment timelines.
What Happened in the Stock Market Today
Mylan plans to merge with a spinoff from Pfizer, and Merck had more good news about its blockbuster cancer drug.
Mylan's Mixed 2nd-Quarter Results Overshadowed by News of Its Upjohn Merger
The drugmaker's revenue improved in the second quarter with new product launches, but higher spending weighed on its earnings.
Why Mylan Stock Is Jumping Today
A proposed combination with Pfizer's Upjohn unit is exciting Mylan shareholders.
